Repligen Corp (RGEN): Operating Income
$55.17M
Year ended 2025-12-31
$64.61M
Trailing 12 months to 2026-06-30
-37.4%
3-year compound annual growth
-4.6%
5-year compound annual growth
+14.9%
10-year compound annual growth
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $55.17M | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | -$35.11M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $47.70M | -78.8% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $224.67M | +34.3% | 2025-03-14, From 2022-01-01 |
| 2021-12-31 | $167.25M | +139.5% | 2024-11-18, From 2021-01-01 |
| 2020-12-31 | $69.82M | +93.5% | 2023-02-22, From 2020-01-01 |
| 2019-12-31 | $36.08M | +38.8% | 2022-02-17, From 2019-01-01 |
| 2018-12-31 | $25.99M | +85.6% | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $14.01M | -12.3% | 2020-02-26, From 2017-01-01 |
| 2016-12-31 | $15.97M | +16.1% | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | $13.76M | +28.7% | 2018-02-22, From 2015-01-01 |
| 2014-12-31 | $10.69M | -53.3% | 2017-02-23, From 2014-01-01 |
| 2013-12-31 | $22.87M | +106.4% | 2016-02-25, From 2013-01-01 |
| 2012-12-31 | $11.08M | n/a | 2015-03-17, From 2012-01-01 |
| No annual figure between 2011-03-31 and 2012-12-31. | |||
| 2011-03-31 | -$374.1K | n/m | 2013-03-15, From 2010-04-01 |
| 2010-03-31 | -$5.77M | n/a | 2012-03-15, From 2009-04-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Repligen Corp (RGEN) | 2025-12-31 | $55.17M | n/m |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $340.99M | n/m |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $191.44M | +37.7% |
| Novavax Inc (NVAX) | 2025-12-31 | $452.80M | n/m |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | -$70.97M | n/m |
| Bio-Techne Corp (TECH) | 2026-06-30 | $251.89M | +146.3% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | -$45.35M | n/m |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $469.01M | -15.0% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $161.29M | +145.3% |
Compare RGEN, BCRX, ADMA, NVAX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗